Skip to content

Treatment of refractory ulcers with Simonkolleite

Treatment of refractory skin ulcers with Simonkolleite

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs021210047
Enrollment
10
Registered
2021-11-18
Start date
2021-11-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory skin ulcer skin ulcer

Interventions

After thoroughly washing and cleaning the skin ulcer surface of the target patient with physiological saline, 6.4 mg of sterilized simoncolite powder per 1 cm2 of ulcer is evenly sprinkled. After spra
Simonkolleite

Sponsors

Norio Fukuda
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who do not show a healing tendency after 3 weeks or more of existing conservative treatments [ointment treatment, wound dressing, basic fibroblast growth factor (bFGF), continuous negative pressure wound therapy (NPWT) etc.] 2. Patients who explained the purpose of this study in a separate document and obtained written consent

Exclusion criteria

Exclusion criteria: 1. Patients with ulcer infection 2. Patients with refractory skin ulcers caused by artificial objects 3. Patients with refractory skin ulcers caused by malignant tumors 4. Patients being treated for malignant tumors 5. Pregnant patients 6. Other patients deemed inappropriate by researchers

Design outcomes

Primary

MeasureTime frame
Detection of adverse findings

Secondary

MeasureTime frame
Reduction rate of ulcer area and volume

Contacts

Public ContactFukuda Norio

Yamagata University Hospital

n-fukuda@med.id.yamagata-u.ac.jp+81-23-628-5413

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026